Ginkgo Bioworks Holdings Inc (NYSE:DNA) currently has a daily average trading volume of 1.52M but it saw 2260541 shares traded in last market. With a market cap of 656.98M USD, the company’s current market price of $11.43 came falling about -9.86 while comparing to the previous closing price of $12.68. In past 52 weeks, the stock remained buoying in the range of price level as high as $64.40 and as low as $5.26.
Taking a look at 20-day trading activity of Ginkgo Bioworks Holdings Inc (DNA) gives us an average price of $13.27, while its current price level is -82.25% below from 52-week high level whereas it is 117.30% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $11.43 while that of 200 days or SMA-200 reads an average of $12.73. A closer look into the stock’s movement over the week reveals that its volatility is standing at 13.80% during that period while stretching the period over a month that decreases to 13.54%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 45.39 which implies that the stock is in neutral territory.
Raymond James also issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $3.50 and $2.50.
Over the week, DNA’s stock price is moving -7.22% down while it is -1.30% when we observe its performance for the past one month. Year-to-date it is 16.40% up and over the past year, the stock is showing a downside performance of -80.56%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -1.3 while estimate for next year EPS is -9.92. In next quarter, company is expected to be making quarterly sales of $44.24M as analysts are expecting the sales for current fiscal year at $227.68M and seeing the company making $203.81M in sales next year. Moreover, analysts are in estimates of $44.43M for current-quarter revenue.
Currently, Ginkgo Bioworks Holdings Inc’s total number of outstanding shares is 41.37M with 6.69% of that held by the insiders while 81.05% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -52.37% and return on equity (ROE) at -63.51%. Stock’s beta reads 1.16. Stock has a price to book (P/B) ratio of 0.72 while price to sale or P/S ratio amounts to 3.01. Its return on asset (ROA) is -37.13% on average.
